eligibility_summary
Eligible: 2–75 y, B‑cell lymphoma, R/R after ≥2 regimens incl anti‑CD20 and anthracycline, ASCT ineligible/refused/relapsed, CD20/19/22+, measurable lesion, ECOG 0–3, adequate marrow/organ, pregnancy test neg, survival ≥3 mo. Exclude: other active cancer, recent immunosuppression/steroids, active infections incl HBV/HCV/HIV/syphilis, uncontrolled CNS disorder, major cardiac dz or QTc>480/LVEF<50, severe allergy, live vaccine, no other trial, pregnant/breastfeeding, active autoimmune on IS.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Multi-targeted autologous CAR-T therapy combining two products—CD19/CD22 dual-target CAR-T and CD19/CD20 dual-target CAR-T—given sequentially as needed. Type: gene-modified T-cell immunotherapy. Mechanism: CARs bind B-cell antigens CD19, CD20, and CD22, antigen engagement triggers CAR signaling (CD3ζ with costimulation), leading to T-cell expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of malignant B cells. Multi-antigen coverage aims to limit antigen-loss escape. Preconditioning: cyclophosphamide (alkylating chemotherapy) plus fludarabine (purine analog antimetabolite) for 3 days to induce lymphodepletion and support CAR-T engraftment/expansion. Cells/pathways targeted: CD19/CD20/CD22-positive B-cell lymphoma cells, immune effector T-cell activation pathways, expected on-target B-cell aplasia. Phase/setting: Phase 1, single-arm, relapsed/refractory B-cell lymphoma.